QuantRx Biomedical Corporation

Equities

QTXB

US74765N1090

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 18:37:42 26/02/2024 GMT			5-day change	1st Jan Change
0.004 ^USD	-.--%		-.--%	-49.37%

2022	QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation	CI

Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020

August 14, 2020 at 08:10 pm

QuantRx Biomedical Corporation announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced operating loss was USD 25,440 compared to USD 61,835 a year ago. Net loss was USD 79,331 compared to USD 97,475 a year ago. For the half year, operating loss was USD 40,840 compared to USD 120,839 a year ago. Net loss was USD 124,003 compared to USD 209,692 a year ago.

Latest news about QuantRx Biomedical Corporation

QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Michael Abrams Resigns as a Member of the Board of Directors of QuantRx Biomedical Corporation	24/08/22	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22/08/22	CI
QuantRx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt	14/04/22	CI
QuantRx Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/11/21	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/08/21	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	17/05/21	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	15/04/21	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	17/11/20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	14/08/20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20/05/20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	14/04/20	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	19/11/19	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	15/08/19	CI
Quantrx Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	20/05/19	CI
Quantrx Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	16/04/19	CI
Preprogen LLC acquired the acquisition of certain assets from QuantRx Biomedical Corporation for $1.4 million.	20/12/17	CI
QuantRx Biomedical Corporation cancelled the acquisition of Global Cancer Diagnostics Inc.	16/08/16	CI
QuantRx Biomedical Corporation signed a letter of intent to acquire Global Cancer Diagnostics Inc.	28/09/15	CI
QuantRx Biomedical Corporation Auditor Raises 'Going Concern' Doubt	14/04/15	CI
QuantRx Biomedical Corporation Announces Demise of William Fleming, President, Chief Scientific Officer and Director	26/03/15	CI
QuantRx Biomedical Mulls Strategic Partners For Point Of Care	19/03/15	CI
QuantRx Biomedical Corporation Provides Update on Technological Progress of its Genomic Diagnostics Platforms	04/03/15	CI

Chart QuantRx Biomedical Corporation

Duration

Period

More charts

Company Profile

QuantRx Biomedical Corporation has developed its patented miniform pads and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs (the OTC Business). The Company is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents (the Diagnostics Business). The Company's platforms include inSync, Unique and original equipment manufacturer (OEM) branded over-the-counter and laboratory testing products based on its core intellectual property related to the Company PAD technology. Its OTC Business includes commercialization of its InSync feminine hygienic interlabial pad, the Unique Miniform for hemorrhoid application, and other treated miniforms, as well as maintaining established and continuing licensing relationships related to the OTC Business. It also owns certain diagnostic testing technology that is based on its lateral flow patents.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
QUANTRX BIOMEDICAL CORPORATION	-49.37%	315K
THERMO FISHER SCIENTIFIC	+11.73%	226B
DANAHER CORPORATION	+9.53%	188B
INTUITIVE SURGICAL, INC.	+14.63%	137B
BOSTON SCIENTIFIC CORPORATION	+27.47%	108B
SIEMENS HEALTHINEERS AG	-0.04%	63.19B
EDWARDS LIFESCIENCES CORPORATION	+13.73%	52.26B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.86%	51B
AGILENT TECHNOLOGIES, INC.	+7.72%	43.89B
GE HEALTHCARE TECHNOLOGIES INC.	+7.86%	38.07B

Other Advanced Medical Equipment & Technology